Human studies have shown PD-L1 expression in residual insulin-positive islets and linked checkpoint pathway disruption to ICI-associated insulin-dependent diabetes in patients receiving anti-PD-1/PD-L1 therapy [178]. The gene discussed is INS; the disease is type 1 diabetes mellitus.